1. Ye, Zhuo, Ren, Chuanchuan, Wang, Qingwei, Wang, Yan. 2022. A novel role of TCAIM: suppressing renal carcinoma growth and enhancing its sensitivity to sunitinib. In The FEBS journal, 289, 5259-5278. doi:10.1111/febs.16417. https://pubmed.ncbi.nlm.nih.gov/35238167/
2. Vogel, Simone Z, Schlickeiser, Stephan, Jürchott, Karsten, Grütz, Gerald, Sawitzki, Birgit. 2015. TCAIM decreases T cell priming capacity of dendritic cells by inhibiting TLR-induced Ca2+ influx and IL-2 production. In Journal of immunology (Baltimore, Md. : 1950), 194, 3136-46. doi:10.4049/jimmunol.1400713. https://pubmed.ncbi.nlm.nih.gov/25750433/
3. Jiahui, Wang, Xiang, Yu, Youhuan, Zhong, Yingjie, Xu, Wen, Yang. 2025. The mitochondrial DNAJC co-chaperone TCAIM reduces α-ketoglutarate dehydrogenase protein levels to regulate metabolism. In Molecular cell, 85, 638-651.e9. doi:10.1016/j.molcel.2025.01.006. https://pubmed.ncbi.nlm.nih.gov/39889707/
4. Krepsova, Eva, Tycova, Irena, Sekerkova, Alena, Sawitzki, Birgit, Viklicky, Ondrej. 2015. Effect of induction therapy on the expression of molecular markers associated with rejection and tolerance. In BMC nephrology, 16, 146. doi:10.1186/s12882-015-0141-2. https://pubmed.ncbi.nlm.nih.gov/26286066/
5. Yamamoto, Takayuki, Iwasaki, Kenta, Murotani, Kenta, Uchida, Kazuharu, Kobayashi, Takaaki. 2018. Peripheral blood immune response-related gene analysis for evaluating the potential risk of chronic antibody-mediated rejection. In Human immunology, 79, 432-438. doi:10.1016/j.humimm.2018.03.012. https://pubmed.ncbi.nlm.nih.gov/29614336/
智鼠故事 
